Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen.

Bright JD, Schultz HN, Byrne JA, Bright RK.

Oncoimmunology. 2013 Jul 1;2(7):e25049. Epub 2013 May 21.


Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.

Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK.

Cancer Immunol Immunother. 2009 Aug;58(8):1337-49. doi: 10.1007/s00262-009-0659-x. Epub 2009 Jan 24.


Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity.

Payton LA, Lewis JD, Byrne JA, Bright RK.

Cancer Immunol Immunother. 2008 Jun;57(6):799-811. Epub 2007 Oct 26.


Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52.

Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, Bright RK.

Mol Cancer Res. 2007 Feb;5(2):133-44.


Overexpressed oncogenic tumor-self antigens.

Bright RK, Bright JD, Byrne JA.

Hum Vaccin Immunother. 2014;10(11):3297-305. doi: 10.4161/hv.29475. Review.


Vaccine therapy of established tumors in the absence of autoimmunity.

Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.

Clin Cancer Res. 2003 May;9(5):1837-49.


Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52.

Shehata M, Bièche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R, Byrne JA.

Clin Cancer Res. 2008 Aug 15;14(16):5050-60. doi: 10.1158/1078-0432.CCR-07-4994.


Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival.

Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, Anderson KS, Ruprecht RM.

Vaccine. 2009 Mar 13;27(12):1825-33. doi: 10.1016/j.vaccine.2009.01.089. Epub 2009 Feb 6.


Partial regulatory T cell depletion prior to schistosomiasis vaccination does not enhance the protection.

Wang X, Liu F, Zhou S, Xu Z, Hoellwarth J, Chen X, He L, Zhang R, Liu F, Wang J, Su C.

PLoS One. 2012;7(7):e40359. doi: 10.1371/journal.pone.0040359. Epub 2012 Jul 3.


A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.

Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, Sakaguchi S, Kang CY.

Cancer Res. 2007 Aug 1;67(15):7477-86.


Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.

Tuve S, Chen BM, Liu Y, Cheng TL, Touré P, Sow PS, Feng Q, Kiviat N, Strauss R, Ni S, Li ZY, Roffler SR, Lieber A.

Cancer Res. 2007 Jun 15;67(12):5929-39.


Accelerating the secondary immune response by inactivating CD4(+)CD25(+) T regulatory cells prior to BCG vaccination does not enhance protection against tuberculosis.

Quinn KM, Rich FJ, Goldsack LM, de Lisle GW, Buddle BM, Delahunt B, Kirman JR.

Eur J Immunol. 2008 Mar;38(3):695-705. doi: 10.1002/eji.200737888.


Regulatory T cells in tumor immunity.

Nishikawa H, Sakaguchi S.

Int J Cancer. 2010 Aug 15;127(4):759-67. doi: 10.1002/ijc.25429. Review.


Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.

Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J, Sparwasser T.

Cancer Res. 2010 Oct 15;70(20):7788-99. doi: 10.1158/0008-5472.CAN-10-1736. Epub 2010 Oct 5.


Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.

Nair S, Boczkowski D, Fassnacht M, Pisetsky D, Gilboa E.

Cancer Res. 2007 Jan 1;67(1):371-80.


HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.

Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR.

J Immunol. 2003 Oct 15;171(8):4054-61.


Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.

Yamamoto M, Kamigaki T, Yamashita K, Hori Y, Hasegawa H, Kuroda D, Moriyama H, Nagata M, Ku Y, Kuroda Y.

Oncol Rep. 2009 Aug;22(2):337-43.


Supplemental Content

Support Center